Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Uncontrolled, Multicenter, Multinational Study on the Efficacy and Safety of Administration of Donor Lymphocytes Depleted of Alloreactive T-cells (ATIR), Through the Use of TH9402 and Light Treatment in an ex Vivo Process, in Patients Receiving a CD34-selected Peripheral Blood Stem Cell Graft From a Related, Haploidentical Donor

NCT00967343 is registered in ClinicalTrials.gov with Kiadis Pharma as lead sponsor.

NCT NCT00967343
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00967343 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Uncontrolled, Multicenter, Multinational Study on the Efficacy and Safety of Administration of Donor Lymphocytes Depleted of Alloreactive T-cells (ATIR), Through the Use of TH9402 and Light Treatment in an ex Vivo Process, in Patients Receiving a CD34-selected Peripheral Blood Stem Cell Graft From a Related, Haploidentical Donor
Lead sponsor
Kiadis Pharma
Phase
Phase 2/3
Overall status
Terminated
Start date
August 31, 2009
Completion date
February 29, 2012
Enrollment
40 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoblastic leukemia, lymphoma, multiple myeloma, myelodysplastic syndrome, myeloid leukemia, myeloproliferative disorders